Company Overview
Teikoku Pharma USA (TPU), a subsidiary of Teikoku Seiyaku, Japan, is an international specialty pharmaceutical company founded in 1997 in California. Teikoku Pharma USA develops innovative products in the CNS, Pain Management and Oncology based on its drug delivery platforms.
Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates, both independently and in collaborations which allows us to enhance the capital resources needed to strengthen our core technologies and expand our product pipeline.
For more than 165 years, our parent company Teikoku Seiyaku Inc., has pursued a vision of developing pharmaceutical products to address unmet needs. A world leader in the research, development, manufacture and commercialization of pharmaceutical drugs.
R & D, Clinical, Regulatory and Manufacturing
At Teikoku Pharma, our capabilities are broad. With a deep expertise in dosage form development and comprehensive manufacturing capabilities, we create both the formulations and the delivery mechanisms that bring innovative ideas to life.
1848
January 7, 1848Shozo Akazawa, the 5th head of the family, obtained a certificate granting him permission from the governments to deal in medicines, and starts business.
1918
December 28, 1918Teikoku Seiyaku was established with capital of 1 million yen in Kagawa Prefecture, Japan.
1974
January 7, 1974Teikoku Seiyaku’s medicated plasters approved for prescription use, becoming the company’s main product line.
1975
January 7, 1975First stage of new production plant for plasters completed. Final stage of construction completed in 1978.
1985
January 7, 1985
Teikoku Kampo Seiyaku Co. Ltd, Teikoku’s subsidiary company that specializes in herbal medicine, was established.
1988
January 7, 1988Catlep, Japan’s first transdermal indomethacin plaster for prescription use, approved and production begins.
1993
January 7, 1993Seltouch, a transdermal felbinac plaster for prescription use, approved and production begins.
